Belgium’s Cardio3, China’s Medisun Join Hands On Phase III Trials In U.S.
This article was originally published in PharmAsia News
Executive Summary
Belgium’s Cardio3 BioSciences secures 25 million euros from China’s Medisun International to aid clinical trial efforts in the United States on a heart failure treatment candidate.
You may also be interested in...
Cardio3 BioSciences’ Stem Cell Heart Therapy Phase III Trials Bolstered By New Funding
Belgian biotech Cardio3 BioSciences is in a leading position in the race to develop a stem cell-based therapy for severe heart failure.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.